56 results about "Sulfotransferase" patented technology

The present invention refers to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are -5-androstene-17-ol, androstane-17-ol-pregnane-17-ol or pregnane-17-ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3β,17-diol or androstane-3β-diol, an enzyme and a sulfotransferase to provide 5-androstene-17-ol-3β-sulfate or corresponding andros tane derivative (17-AEDS or 17-AADS); and mixing the 17-AEDS or 17-AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor-(PPAR) is produced.

An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.

An intracellular selection system allows concurrent screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at either the N-terminus, the C-terminus, or both. The stabilizing group can take the form of a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, or one or more proline residues.

The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs against N-acetylgalactosamine-4-O-sulfotransferases (N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, and N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, and GALNAC4S-6ST, respectively)), which are sulfotransferases for acetylgalactosamine, a CSPG side chain, and chondroitinase ABC, an enzyme that degrades chondroitin sulfate, another CSPG side chain.

A galactosamine derivative represented by the following formula (1):

wherein R₁, R₂ and R₅ each independently represents SO₃⁻ or H, and at least one of them represents SO₃⁻; R₃ represents H, acetyl or SO₃⁻; R₄ represents H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; X represents O, S, NH or CH₂; and represents an α bond or a β bond, and a sulfotransferase inhibitor comprising the derivative.

The present invention relates to hepatic fibrosis-suppressing agents that are suitable for treating or preventing fibrotic liver diseases such as cirrhosis, which comprise as an active ingredient a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycans including chondroitinase ABC and ADAMTS-4; and methods of screening for the agents.

The present inventors discovered for the first time that hepatic fibrosis could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, fibrosis of liver tissues can be suppressed by administering chondroitinase ABC, a chondroitin sulfate proteoglycan-degrading enzyme, or by using siRNA to suppress the expression of C4ST-1, C6ST-1, or C6ST-2, a sulfotransferase for chondroitin sulfate proteoglycans. Compounds such as nucleic acids that are used as siRNA can be used as effective agents for suppressing hepatic fibrosis. Furthermore, hepatic fibrosis-suppressing agents can be found by screening for compounds that suppress the production or accumulation of chondroitin sulfate proteoglycans.

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) performing an assay on a biological sample obtained from the patient to detect fucosylated prostate specific antigen (PSA), transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, prostatic acid phosphatase (PAP), nuclear RNA export factor 2, and protein POF1B; and (b) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated PSA, transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, PAP, nuclear RNA export factor 2, and protein POF1B as compared to corresponding levels in a control sample that correlates to non-aggressive prostate cancer.

The invention discloses a recombinant bacterium for producing sulfo-recombinant hirudin as well as a preparation method and application of the recombinant bacterium, and belongs to the technical field of genetic engineering. In order to improve the synthesis yield of the sulfated recombinant hirudin and reduce the production cost, the invention provides the recombinant bacterium for producing the sulfo-recombinant hirudin, wherein the recombinant bacterium overexpresses a sulfotransferase gene and a hirudin gene, and an original strain is escherichia coli; and the nucleotide sequence of the hirudin gene is one of SEQ ID No.1 to SEQ ID No.3, and the nucleotide sequence of the sulfotransferase gene is as shown in SEQ ID No.4. According to the method, the activity of the recombinant hirudin is remarkably improved, a one-step purification method of the hirudin is realized, a recombinant hirudin product with relatively high purity can be obtained at one time, and the pressure of subsequent purification is greatly reduced.

The object of the present invention is to provide a method for detecting gynecologic cancer and a kit for detecting the same.

The object can be solved by a method for detecting gynecologic cancer characterized in that β1,3-galactosyltransferase-5 and/or β1,3-galactosyltransferase-4, and GlcNAc 6-O-sulfotransferase-2 are analyzed. According to the detecting method, ovarian cancer and endometrial cancer patients can be detected at an early stage i.e. stages I and II, wherein patients have no subjective symptoms.

The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas.

The hexuronic acid derivative represented by the following formula 1 or a salt thereof is used as an active ingredient of a heparin/heparan sulfate sulfotransferase inhibitor.

In the formula, each of R₁, R₂, and R₃ independently represent(s) SO₃⁻ or H which may have a substituent, provided that at least one thereof represents SO₃⁻; X represents OR₄, SR₄, N(R₄)₂, or C(R₄)₃, R₄ independently represents H, alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R₅ and R₆ represents COOH while the other represents H; and the wavy line represents α-glycosidic bond or β-glycosidic bond.

The invention provides an isolated polypeptide encoding a corneal N-acetylglucosamine-6-sulfotransferase (GlcNAc6ST) or active fragment thereof, where the GlcNAc6ST or active fragment thereof catalyzes sulfation of keratan sulfate. The present invention also provides a method of treating a subject with macular corneal dystrophy. The method includes the steps of administering to the subject an effective amount of an agent that increases expression or activity of a GlcNAc6ST, whereby the amount of sulfated keratan sulfate in the cornea of the subject is elevated. A method of the invention can be used to treat macular corneal dystrophy type I or type II.

The invention discloses recombinant strains expressing a chondroitin 4-sulfotransferase gene and an applicationof the recombinant strain, and relates to the technical field of bioengineering. Chondroitin 4-sulfotransferase gene with the amino acid sequence shown in SEQ ID NO.1 is expressed with Escherichia coli or bacillus subtilis as a host, four recombinant strains are constituted, the high-efficiency expression of chondroitin 4-sulforansferase gene is realized, and final enzyme activity respectively reaches 41.3 U/mL, 32.8 U/mL, 36.5 U/mL and 50.2 U/mL. By using the enzyme as a catalyst, chondroitin sulfate A is catalyzed and synthesis in one step with chondroitin as a substrate, the final conversion efficiency reaches 80%. The method has potential and quite wide values in industrial synthesis of chondroitin sulfate A.

A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I:

GlcNAcβ1-3Gal β1-4GlcNAc  (I)

wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, β1-3 represents a β1-3 glycosidic linkage, and β1-4 represents a β1-4 glycosidic linkage.

The invention discloses a leech tyrosine sulphonate transferase gene and application thereof, and belongs to the field of biomedicine. The leech tyrosine sulphonate transferase gene is characterized in that on the basis of a hirudo nipponia transcriptome database, a leech tyrosine sulphonate transferase cDNA sequence is excavated and identified through a bioinformatics means, and on this basis, the leech tyrosine sulfotransferase is synthesized through codon optimization, gene synthesis and microbial cell expression, and the recombinant hirudin is catalyzed by the leech tyrosine sulfotransferase to be subjected to sulfonation modification to obtain the natural hirudin. The catalytic ability of the transferase is greatly improved compared with that of acyl sulfonate transferase, human-derived tyrosine sulfonate transferase and bovine-derived tyrosine sulfonate transferase. Compared with other tyrosine sulfonic acid transferase, the leech tyrosine sulfonic acid transferase obtained in the invention has stronger substrate preference for recombinant hirudin, is suitable for large-scale preparation of natural hirudin, and provides a new way for synthesis of natural hirudin.

Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

The invention pertains to the identification and isolation of a gene involved in the boar taint phenotype. A porcine form of a gene, designated SULT2A1, is identified. The invention additionally provides methods of inhibiting or reducing boar taint using the novel SULT2A1 gene or gene product. Methods for reducing or inhibiting boar taint and methods for screening compounds to modulate SULT2A1 are also disclosed.